Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
Roche announced data from a 5-year follow-up of the pivotal phase III POLARIX study. Data were presented in an oral session at the 66th American Society of Hematology… read more.
